Also, those with low riskScore had more sensitivity to drugs, such as midostaurin and sorafenib, that modulate the receptor tyrosine kinase FLT3; the former has been approved as a new treatment option for relapsed or refractory FLT3-mutated AML (Figures 5G–I). This evidence concerns the gene FLT3 and acute myeloid leukemia.